Results 81 to 90 of about 2,330,708 (370)

Natural immunogenic properties of bioinformatically predicted linear B-cell epitopes of dengue envelope and pre-membrane proteins

BMC Immunology, 2021
Background The natural antibody responses to B-cell epitopes from dengue structural proteins were assessed using immune sera from people having well-defined past dengue infections with one of the four serotypes.
Mahesha N. Nadugala, Chandima Jeewandara, Ramesh S. Jadi, Gathsaurie N. Malavige, Aravinda M. de Silva, Prasad H. Premaratne, Charitha L. Goonasekara   +6 more
doaj   +1 more source

Leveraging current insights on IL‐10‐producing dendritic cells for developing effective immunotherapeutic approaches

FEBS Letters, EarlyView.
In vivo IL‐10 produced by tissue‐resident tolDC is involved in maintaining/inducing tolerance. Depending on the agent used for ex vivo tolDC generation, cells acquire common features but prime T cells towards anergy, FOXP3+ Tregs, or Tr1 cells according to the levels of IL‐10 produced. Ex vivo‐induced tolDC were administered to patients to re‐establish/
Konstantina Morali, Gloria Giacomello, Michela Vuono, Silvia Gregori   +3 more
wiley   +1 more source

The immunological interface: dendritic cells as key regulators in metabolic dysfunction‐associated steatotic liver disease

FEBS Letters, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) affects nearly one‐third of the global population and poses a significant risk of progression to cirrhosis or liver cancer. Here, we discuss the roles of hepatic dendritic cell subtypes in MASLD, highlighting their distinct contributions to disease initiation and progression, and their ...
Camilla Klaimi, WanTing Kong, Camille Blériot, Joel T. Haas   +3 more
wiley   +1 more source

Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing Gn protects mice against rift valley fever virus [PDF]

, 2010
Background: Rift Valley fever (RVF) is an arthropod-borne viral zoonosis. Rift Valley fever virus (RVFV) is an important biological threat with the potential to spread to new susceptible areas. In addition, it is a potential biowarfare agent. Methodology/
A Jouan, A Zaki, B Botros, BH Bird, BS Peters, CS Schmaljohn, CS Schmaljohn, Daniel G. Bausch, DB Wallace, DV Lim, FR Toapanta, FR Toapanta, G Lorenzo, GF Meadors 3rd, H Caplen, I Watanabe, J Lubroth, J Meegan, J Naslund, J Naslund, JA Mitchell, JF Bower, JF Bower, JR Haynes, JT van Oirschot, K Keegan, K Spik, KA Hubbard, M Mkrtichyan, MA Kutzler, Mark T. Heise, MT Heise, N Lagerqvist, Nitin Bhardwaj, P Hunter, P Jansen van Vuren, P Nguku, P Pittman, P Pushko, P Vialat, PR Pittman, PW Dempsey, R Gorchakov, R Gorchakov, R Randall, RJ Daubney, S Won, SA Kamal, SR Gerrard, SR Gerrard, T Shoemaker, TA Madani, TD Green, Ted M. Ross, TM Pertmer, TM Pertmer, TM Ross, TM Ross, UB Balasuriya   +58 more
core   +4 more sources

COMPARATIVE CHARACTERISTIC'S OF IMMUNE STATUS OF PAT I ENTS WITH CHRONIC FORMS OF VIRAL HEPATITIS В, C, D AND HEALTHY INDIVIDUALS

Журнал микробиологии, эпидемиологии и иммунобиологии, 2017
Aim. Evaluate immune status in patients with chronic hepatitis (CH) depending on type of causative agent and severity of the infectious process. Materials and methods.
S. I. Semenov, A. I. Fedorov, S. S. Maksimova, K. M. Stepanov, F. A. Platonov   +4 more
doaj   +1 more source

Insights into PI3K/AKT signaling in B cell development and chronic lymphocytic leukemia

FEBS Letters, EarlyView.
This Review explores how the phosphoinositide 3‐kinase and protein kinase B pathway shapes B cell development and drives chronic lymphocytic leukemia, a common blood cancer. It examines how signaling levels affect disease progression, addresses treatment challenges, and introduces novel experimental strategies to improve therapies and patient outcomes.
Maike Buchner
wiley   +1 more source

The "erythrocyte-coating substance" of "auto-immune" hemolytic disease [PDF]

, 1957
Thesis (M.A.)--Boston ...
Fudenberg, Hugh
core  

Cholestatic liver disease after rituximab and adalimumab and the possible role of cross-reacting antibodies to Fab 2 fragments. [PDF]

PLoS ONE, 2013
BACKGROUND: Millions of patients are treated with therapeutic monoclonal antibodies (Tmabs) for miscellaneous diseases. We investigated sera from six patients who received immune globulin, from one patient with refractory anti-neutrophil-cytoplasmic ...
Joerg Latus, Reinhild Klein, Ina Koetter, Matthias Schwab, Peter Fritz, Martin Kimmel, M Dominik Alscher, Niko Braun   +7 more
doaj   +1 more source

Clq and immune complexes in liver cirrhosis sera.

The Tohoku Journal of Experimental Medicine, 1983
The highest mean value of the serum C1q concentrations among chronic liver diseases was obtained in patients with liver cirrhosis (LC). C1q serum levels seemed to increase along the progression of liver damage. Serum levels of C1q and CH50 in patients with LC and systemic lupus erythematosus (SLE) were simultaneously estimated.
Reiji Kasukawa, Masahiko Nakai, Mikio Sato, Takao Morito, Hiroshi Yoshida, Tomoe Nishimaki, Susumu Watanabe   +6 more
openaire   +4 more sources

Circulating immune complexes in colon cancer patient sera [PDF]

Cancer, 1979
Sera from 29 colon cancer patients and 16 elderly normal controls were compared using the Raji radioimmunoassay and the Clq binding assay. By the Raji assay 11 of 29 cancer patients had evidence of circulating complexes, while by the Clq assay only 4 of the 29 patients had complexes. There was no significant difference between the levels of circulating
Charles F. McKhann, Roger D. Rossen, David S. Fryd, Sandra S. Ristow   +3 more
openaire   +2 more sources